3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Tumor-Agnostic
4
Breast
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Conditions
Brain Neoplasms
3
Glioblastoma
2
Breast Neoplasms
2
Recurrence
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Interventions
Radiosurgery
33
Radiotherapy
19
Temozolomide
16
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
7
Cyclophosphamide
7
trastuzumab deruxtecan
4
temsirolimus
4
Sunitinib
4
Specimen Handling
4
Mental Status and Dementia Tests
4
motexafin gadolinium
3
fludarabine phosphate
3
fludarabine
3
aldesleukin
3
Trastuzumab
3
Pemetrexed
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Dexamethasone
3
Capecitabine
3
Bevacizumab
3
pembrolizumab
2
entrectinib
2
efaproxiral
2
Vinorelbine
2
Topotecan
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Quality of Life
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
cabazitaxel
×
CNS
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled